It has been demonstrated in vitro that the migration of human haemopoietic stem cells (HSC) toward a bone marrow stromal cell-derived factor-1 (SDF-1) gradient is dependent on the expression of the chemokine receptor CXCR4.
It has been demonstrated in vitro that the migration of human haemopoietic stem cells (HSC) toward a bone marrow stromal cell-derived factor-1 (SDF-1) gradient is dependent on the expression of the chemokine receptor CXCR4. 1, 2 Furthermore, the establishment of human multilineage haemopoiesis in a murine NOD/SCID xenograft model can be abolished if the human HSC are pre-incu- bated with antibodies directed against CXCR4. 3 This has led to the notion that HSC CXCR4 expression may play a crucial role in HSC transplantation by determining the efficiency with which HSC localise to the bone marrow compartment. The influence this may have on putative ex vivo HSC expansion strategies has recently been highlighted by the observed downmodulation of SDF-1 responsiveness following prolonged in vitro IL-3 exposure. 2 We have measured CXCR4 expression on HSC mobilised from normal donors and sought to establish whether there is any relationship between the number of infused CXCR4-positive HSC and engraftment following allogeneic peripheral blood haemopoietic stem cell (PBSC) transplantation.
Patients and methods
PBSC were obtained from normal donors (n ϭ 16) treated with granulocyte colony-stimulating factor (G-CSF) after obtaining written informed consent as per institutional guidelines. PBSC mononuclear cells were isolated by density gradient centrifugation and CD34-positive cells were then selected using the Dynal CD34 Progenitor Cell Selection System (Dynal, Oslo, Norway) as per the manufacturer's instructions (post-selection median CD34-positive cell purity 77%, range 40-95%). Following incubation with Intragam (CSL, Parkville, Australia) to prevent non-specific FcR binding, cells were doubled stained with anti-CD34 FITC (Becton Dickinson, San Jose, CA, USA) and anti-CXCR4 PE (clone 12G5; Pharmingen, San Diego, CA, USA) or with anti-IgG1 FITC and anti-IgG2a PE isotype controls. In each instance the proportion of CD34-positive cells co-expressing CXCR4 was enumerated on a FACScan flow cytometer with CELLQuest software (Becton Dickinson). Total CD34-positive PBSC numbers available for transplantation were measured separately by CD34-positive cell enumeration on unmanipulated PBSC samples as per the ISHAGE guidelines. 4 The number of CXCR4 CD34 double-positive cells available for transplantation was calculated.
Subsequently, 16 adult patients with haematological malignancies underwent allogeneic transplantation with the harvested PBSC. G-CSF was not used post transplant. Times to neutrophil (the first of 3 consecutive days with a neutrophil count Ͼ0.5 ϫ 10 (the first of 3 consecutive days with a platelet count Ͼ20 ϫ 10 9 /l unsupported) were documented along with donor type (related vs unrelated), HLA match (fully matched vs mismatched), graft-versus-host disease prophylaxis (methotrexate vs no methotrexate), conditioning (myeloablative vs non-myeloablative), CD34-positive cell dose (greater than the median vs less than or equal to the median) and CXCR4 CD34 double-positive cell dose (greater than the median vs less than or equal to the median). Differences in times to engraftment based on the above transplant-related characteristics were sought using the Mann-Whitney U test.
Results
The median number of CD34-positive cells expressing CXCR4 was 41% with a range of 16% to 76% (Figure 1 ). The actual median cell doses infused at transplantation were 6.4 ϫ 10 6 CD34-positive cells/kg recipient body weight (range 4.1-23.2) and 2.5 ϫ 10 6 CXCR4 CD34 double-positive cells/kg recipient body weight (0.8-10.3). Fifteen of the 16 transplant recipients were evaluable for neutrophil and platelet engraftment with median times to engraftment of 13 days (range, 10-23 days) and 11 days (range, 9-42 days), respectively. No significant differences in the time to neutrophil or platelet engraftment were observed based on donor type, HLA match, graft-versushost disease prophylaxis or conditioning regimen. No significant difference in the times to neutrophil engraftment was seen with the higher or lower CD34-positive or CXCR4 CD34 double-positive cell doses. Likewise, there was no significant difference in the times to platelet engraftment between the higher and lower CD34-positive cell doses. In contrast, patients receiving a higher dose of CXCR4 CD34 double-positive cells demonstrated a significant shortening of the time to platelet engraftment compared to the recipients of the lower CXCR4 CD34 double-positive cell doses (10 days vs 14.5 days, respectively, P ϭ 0.02) (Figures 2 and 3) . All but one of the recipients of the higher CXCR4 CD34 double-positive cell doses achieved platelet engraftment by day 11.
Discussion
The majority of normal donor-mobilised CD34-positive HSC did not express CXCR4 but there was considerable variation in CXCR4 expression between the different donors. This inter-individual variation in CXCR4 expression was similar to that reported in a small cohort of patients with haematological malignancies undergoing HSC mobilisation. 5 The latter information combined with data from in vitro migration and NOD-SCID xenograft experi- 2, 3 suggests that only a minority of infused CD34-positive HSC may actually be capable of contributing to post-transplant haemopoietic reconstitution. Our engraftment data support this notion by demonstrating for the first time that the expression of CXCR4 may be an important determinant of post-transplant engraftment and that a minimum threshold number of CXCR4 CD34 double-positive cells may be required to ensure rapid post-transplant platelet engraftment.
Data published over the past decade have defined minimum threshold progenitor cell doses for autologous PBSC transplantation ensuring rapid post-transplant platelet and neutrophil engraftment. 6 Data do not exist for allogeneic PBSC transplantation but it is not unreasonable to assume that engraftment kinetics will be similar to those in autologous PBSC transplantation. In the latter, the relationship between CD34 content and haemopoietic recovery is nonlinear whereby increasing cell doses above the defined minimum thresholds result in only small further reductions in the times to engraftment. [6] [7] [8] [9] Intuitively this would be expected because if the cell dose is no longer a limiting variable on engraftment, the time to achieving engraftment (neutrophil and platelet recovery within the peripheral blood) is determined by the lag phase between the infused stem cell 'engrafting' within the bone marrow microenvironment and the time required for cell maturation, differentiation and release into the blood stream. Variations in engraftment times for patients with adequate stem cell inoculums are therefore most likely due to other confounding factors.
In the autologous PBSC transplant setting CD34-positive cell doses of Ͼ2.5 million/kg body weight result in a 95% probability of rapid neutrophil engraftment. In contrast, a higher CD34 cell dose (Ͼ5.0 million/kg body weight) is necessary to provide a similar assurance of platelet engraftment. 7 In our cohort all transplant recipients received Ͼ4.0 million CD34 cells/kg body weight, therefore, we feel that no correlation between CXCR4 CD34 double-positive cell dose and neutrophil recovery was seen because all patients (including those in the low-dose group) probably received well above the minimum threshold CD34 cell dose (and probably also the CXCR4 CD34 doublepositive cell dose) required for rapid neutrophil recovery. We feel that a relationship between CXCR4 CD34 doublepositive cell dose and neutrophil engraftment is likely to exist but current practice (at least in our unit with a target CD34 cell dose of Ͼ4.0 million CD34 cells/kg body weight) dictates that in vivo, such a relationship will be difficult to prove. We feel our data, based on the relationship between CXCR4 CD34 double-positive cell dose and platelet engraftment, support the idea that CXCR4 CD34 double-positive cell dose may be biologically more relevant and therefore a more useful predictor of engraftment than total CD34 dose.
Whether the expression of CXCR4 on infused CD34-positive cells is critical for subsequent engraftment is uncertain. Murine studies have shown a markedly reduced repopulation potential for sorted CXCR4-negative CD34 ϩ /CD38 Ϫ /Lin Ϫ cord blood cells when compared to the entire CD34 ϩ /CD38 Ϫ /Lin Ϫ population. 10, 11 Furthermore, pre-incubation with anti-CXCXR4 antibodies leads
Bone Marrow Transplantation to the abolition of human progenitor cell engraftment within a NOD SCID model. 3 Taken together, these data and our own observations, whilst not conclusive, do support the notion that CXCR4 expression may be critical for in vivo stem cell homing and engraftment. The fate of infused CXCR4-negative progenitors is uncertain. However, one could speculate that after a critical time period outside of the bone marrow microenvironment they undergo apoptosis.
Our observations provide a rationale for measuring CXCR4 CD34 double-positive cell numbers pre-transplant to enable the adequacy of HSC inocula to be more accurately evaluated. In addition, the preliminary evidence that CXCR4 expression 3 or SDF-1 responsiveness 2,12 can be modulated in vitro following cytokine exposure raises the theoretical possibility that the ability of HSC inocula needed to provide rapid engraftment may be able to be enhanced in vitro. If successful, this could be a simpler alternative to ex vivo HSC expansion strategies and may have important implications for the future safe use of cord blood HSC transplantation and in other instances where only borderline HSC inocula are available.
